Paradigm Therapeutics
Mt Pleasant, US · 1 known investors
Paradigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder. The company focuses on discovering and delivering therapies for patients with serious, life-threatening diseases.
Founders & leadership
RR
Robert RyanDr.
Investors · 1
Frequently asked questions
- What does Paradigm Therapeutics do?
- Paradigm Therapeutics is a biopharmaceutical company developing Zorblesia (SD-101), a proprietary topical whole-body therapy for treating the wounds, lesions, and infections associated with all subtypes of Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder. The company focuses on discovering and delivering therapies for patients with serious, life-threatening diseases.
- Who are Paradigm Therapeutics's investors?
- Paradigm Therapeutics's investors include Eshelman Ventures, LLC.
- Where is Paradigm Therapeutics headquartered?
- Paradigm Therapeutics is headquartered in Mt Pleasant, US.